Literature DB >> 29080741

Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.

Sanders Oh1, John A Kessler2.   

Abstract

Proteins are drivers of cell functions and are targets of many therapies. Exogenous protein expression techniques, therefore, have been essential for research and medicine. The most common method for exogenous protein expression relies on DNA-based viral or non-viral vectors. However, DNA-based vectors have the potential to integrate into the host genome and cause permanent mutations. RNA-based vectors solve this shortcoming. In particular, synthetic modified mRNA provides non-viral, integration-free, zero-footprint method for expressing proteins. Modified mRNA can direct cell fate specification and cellular reprogramming faster and more efficiently than other methods. Furthermore, when simultaneously express multiple different proteins, mRNA vectors allow for greater flexibility and control over stoichiometric ratios, dose titrations, and complete silencing of expressions. Additionally, modified mRNAs have been shown to be viable and safe as therapeutic agents for gene therapy and vaccine, providing an alternative approach to address diseases. Despite these advantages, technical challenge, mRNA instability, and host immunogenicity have caused significant barriers to widespread use of this technology. The comprehensive method presented here addresses all of these shortcomings. This stepwise protocol describes every step necessary for the synthesis of modified mRNA from any coding DNA sequence of interest. The meticulously detailed protocol enables the users to make alterations to each component of modified mRNA for even more significant customization, allowing the researchers to apply this technology to a wide range of uses. This non-cytotoxic synthetic modified mRNA can be used for protein expression, regulation of cell reprogramming or differentiation, and drug delivery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Messenger RNA; Modified mRNA; Reprogramming factors; Synthetic mRNA; mRNA protocol; mRNA reprogramming; mRNA synthesis; mRNA transfection

Mesh:

Substances:

Year:  2017        PMID: 29080741      PMCID: PMC5807177          DOI: 10.1016/j.ymeth.2017.10.008

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  55 in total

1.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.

Authors:  Silke Holtkamp; Sebastian Kreiter; Abderraouf Selmi; Petra Simon; Michael Koslowski; Christoph Huber; Ozlem Türeci; Ugur Sahin
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 2.  Modulation of mRNA stability as a novel therapeutic approach.

Authors:  Wolfgang Eberhardt; Anke Doller; El-Sayed Akool; Josef Pfeilschifter
Journal:  Pharmacol Ther       Date:  2007-01-25       Impact factor: 12.310

3.  In vivo and in vitro analysis of poly(A) length effects on mRNA translation.

Authors:  Jing Peng; Elizabeth L Murray; Daniel R Schoenberg
Journal:  Methods Mol Biol       Date:  2008

4.  Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays.

Authors:  Mehrije Ferizi; Carolin Leonhardt; Christian Meggle; Manish K Aneja; Carsten Rudolph; Christian Plank; Joachim O Rädler
Journal:  Lab Chip       Date:  2015-07-23       Impact factor: 6.799

5.  Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression.

Authors:  Linzhao Cheng; Nancy F Hansen; Ling Zhao; Yutao Du; Chunlin Zou; Frank X Donovan; Bin-Kuan Chou; Guangyu Zhou; Shijie Li; Sarah N Dowey; Zhaohui Ye; Settara C Chandrasekharappa; Huanming Yang; James C Mullikin; P Paul Liu
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

6.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Authors:  Michael S D Kormann; Günther Hasenpusch; Manish K Aneja; Gabriela Nica; Andreas W Flemmer; Susanne Herber-Jonat; Marceline Huppmann; Lauren E Mays; Marta Illenyi; Andrea Schams; Matthias Griese; Iris Bittmann; Rupert Handgretinger; Dominik Hartl; Joseph Rosenecker; Carsten Rudolph
Journal:  Nat Biotechnol       Date:  2011-01-09       Impact factor: 54.908

7.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

8.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.

Authors:  D Caput; B Beutler; K Hartog; R Thayer; S Brown-Shimer; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.

Authors:  Kyle K L Phua; Kam W Leong; Smita K Nair
Journal:  J Control Release       Date:  2013-01-07       Impact factor: 9.776

10.  Rapid differentiation of human pluripotent stem cells into functional neurons by mRNAs encoding transcription factors.

Authors:  Sravan Kumar Goparaju; Kazuhisa Kohda; Keiji Ibata; Atsumi Soma; Yukhi Nakatake; Tomohiko Akiyama; Shunichi Wakabayashi; Misako Matsushita; Miki Sakota; Hiromi Kimura; Michisuke Yuzaki; Shigeru B H Ko; Minoru S H Ko
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

View more
  11 in total

1.  Optimization of Synthetic mRNA for Highly Efficient Translation and its Application in the Generation of Endothelial and Hematopoietic Cells from Human and Primate Pluripotent Stem Cells.

Authors:  Kran Suknuntha; Lihong Tao; Vera Brok-Volchanskaya; Saritha S D'Souza; Akhilesh Kumar; Igor Slukvin
Journal:  Stem Cell Rev Rep       Date:  2018-08       Impact factor: 5.739

Review 2.  mRNA vaccine for cancer immunotherapy.

Authors:  Lei Miao; Yu Zhang; Leaf Huang
Journal:  Mol Cancer       Date:  2021-02-25       Impact factor: 27.401

3.  Transfection types, methods and strategies: a technical review.

Authors:  Zhi Xiong Chong; Swee Keong Yeap; Wan Yong Ho
Journal:  PeerJ       Date:  2021-04-21       Impact factor: 2.984

Review 4.  mRNA vaccines for COVID-19: what, why and how.

Authors:  Jung Woo Park; Philip N P Lagniton; Yu Liu; Ren-He Xu
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

5.  Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.

Authors:  Rodolfo E De La Vega; Martijn van Griensven; Wen Zhang; Michael J Coenen; Christopher V Nagelli; Joseph A Panos; Carlos J Peniche Silva; Johannes Geiger; Christian Plank; Christopher H Evans; Elizabeth R Balmayor
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

6.  mRNA Transfection-Induced Activation of Primary Human Monocytes and Macrophages: Dependence on Carrier System and Nucleotide Modification.

Authors:  Hanieh Moradian; Toralf Roch; Andreas Lendlein; Manfred Gossen
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

Review 7.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

Review 8.  Genetic glycoengineering in mammalian cells.

Authors:  Yoshiki Narimatsu; Christian Büll; Yen-Hsi Chen; Hans H Wandall; Zhang Yang; Henrik Clausen
Journal:  J Biol Chem       Date:  2021-02-20       Impact factor: 5.157

Review 9.  Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through.

Authors:  Narmatha Gurumoorthy; Fazlina Nordin; Gee Jun Tye; Wan Safwani Wan Kamarul Zaman; Min Hwei Ng
Journal:  Biomedicines       Date:  2022-01-05

Review 10.  mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.

Authors:  Andreas Ouranidis; Theofanis Vavilis; Evdokia Mandala; Christina Davidopoulou; Eleni Stamoula; Catherine K Markopoulou; Anna Karagianni; Kyriakos Kachrimanis
Journal:  Biomedicines       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.